Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF for SBP with Septic Shock
NCT04208763Phase 3Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of sargramostim in spontaneous bacterial peritonitis (SBP), septic shock, sponsored by Institute of Liver and Biliary Sciences. Status: unknown.
02
Drugs
sargramostim
03
Conditions
spontaneous bacterial peritonitis (SBP)septic shock
Beyond the preview
Go deeper on NCT04208763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04208763.